Early tolerability of Comirnaty vaccine in patients with chronic neurological diseases

Patients with chronic neurological diseases may have predisposing risk factors for severe COVID-19 and should be considered as priority candidates for SARS-CoV-2 vaccination. Nevertheless, the safety of RNA vaccine was evaluated in healthy volunteers or in patients with stable chronic medical condit...

Descripción completa

Detalles Bibliográficos
Autores principales: Budowski, C., Zavanone, C., Thivard, L., Vassilev, K., Dupont, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Masson SAS. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511656/
https://www.ncbi.nlm.nih.gov/pubmed/34654546
http://dx.doi.org/10.1016/j.neurol.2021.05.005
_version_ 1784582814238244864
author Budowski, C.
Zavanone, C.
Thivard, L.
Vassilev, K.
Dupont, S.
author_facet Budowski, C.
Zavanone, C.
Thivard, L.
Vassilev, K.
Dupont, S.
author_sort Budowski, C.
collection PubMed
description Patients with chronic neurological diseases may have predisposing risk factors for severe COVID-19 and should be considered as priority candidates for SARS-CoV-2 vaccination. Nevertheless, the safety of RNA vaccine was evaluated in healthy volunteers or in patients with stable chronic medical conditions excluding patients with chronic neurological diseases. We report here the early tolerability of Comirnaty vaccine in 36 patients with chronic neurological diseases and demonstrate good early tolerability, better than found in healthy people in phase 3 trials.
format Online
Article
Text
id pubmed-8511656
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Published by Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-85116562021-10-13 Early tolerability of Comirnaty vaccine in patients with chronic neurological diseases Budowski, C. Zavanone, C. Thivard, L. Vassilev, K. Dupont, S. Rev Neurol (Paris) Original Article Patients with chronic neurological diseases may have predisposing risk factors for severe COVID-19 and should be considered as priority candidates for SARS-CoV-2 vaccination. Nevertheless, the safety of RNA vaccine was evaluated in healthy volunteers or in patients with stable chronic medical conditions excluding patients with chronic neurological diseases. We report here the early tolerability of Comirnaty vaccine in 36 patients with chronic neurological diseases and demonstrate good early tolerability, better than found in healthy people in phase 3 trials. Published by Elsevier Masson SAS. 2021-12 2021-10-13 /pmc/articles/PMC8511656/ /pubmed/34654546 http://dx.doi.org/10.1016/j.neurol.2021.05.005 Text en © 2021 Published by Elsevier Masson SAS. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Budowski, C.
Zavanone, C.
Thivard, L.
Vassilev, K.
Dupont, S.
Early tolerability of Comirnaty vaccine in patients with chronic neurological diseases
title Early tolerability of Comirnaty vaccine in patients with chronic neurological diseases
title_full Early tolerability of Comirnaty vaccine in patients with chronic neurological diseases
title_fullStr Early tolerability of Comirnaty vaccine in patients with chronic neurological diseases
title_full_unstemmed Early tolerability of Comirnaty vaccine in patients with chronic neurological diseases
title_short Early tolerability of Comirnaty vaccine in patients with chronic neurological diseases
title_sort early tolerability of comirnaty vaccine in patients with chronic neurological diseases
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511656/
https://www.ncbi.nlm.nih.gov/pubmed/34654546
http://dx.doi.org/10.1016/j.neurol.2021.05.005
work_keys_str_mv AT budowskic earlytolerabilityofcomirnatyvaccineinpatientswithchronicneurologicaldiseases
AT zavanonec earlytolerabilityofcomirnatyvaccineinpatientswithchronicneurologicaldiseases
AT thivardl earlytolerabilityofcomirnatyvaccineinpatientswithchronicneurologicaldiseases
AT vassilevk earlytolerabilityofcomirnatyvaccineinpatientswithchronicneurologicaldiseases
AT duponts earlytolerabilityofcomirnatyvaccineinpatientswithchronicneurologicaldiseases

Ejemplares similares